Search

Search Constraints

You searched for: Author/Creator Arai, Hirotaka

Search Results

1. Analyses of objective response rate, progression‐free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. Issue 3 (10th December 2019)

2. Changes of esophageal varices in hepatitis C patients after achievement of a sustained viral response by direct‐acting antivirals. Issue 1 (5th July 2021)

3. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group. Issue 7 (18th May 2022)

4. Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin. Issue 3 (25th September 2017)

5. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon‐occluded transcatheter arterial chemoembolization: A retrospective cohort study. Issue 2 (22nd June 2017)

6. Favorable outcome of retreatment by direct‐acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure. Issue 3 (19th December 2019)

7. Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Issue 11 (3rd July 2021)

8. Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Issue 1 (20th October 2020)

9. Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Issue 1 (20th October 2020)